409 related articles for article (PubMed ID: 19922884)
1. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
3. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
5. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
6. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
7. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
8. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
9. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
Tschirner M; Ritzdorf I; Brünjes R
MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
17. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
[TBL] [Abstract][Full Text] [Related]
18. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
[TBL] [Abstract][Full Text] [Related]
19. Low morphine doses in opioid-naive cancer patients with pain.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Ficorella C; Verna L; Tirelli W; Villari P; Arcuri E
J Pain Symptom Manage; 2006 Mar; 31(3):242-7. PubMed ID: 16563318
[TBL] [Abstract][Full Text] [Related]
20. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
Barutell C; Camba A; González-Escalada JR; Rodríguez M;
Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
